Arthritis drug withdrawn

My Account
Logout

Create an Evening Standard Account

Use your social network

Save time by using your existing account to sign in to Evening Standard

We'll never share your information or post anything to your account without your permission

Welcome! Sign in here

Use your social network

Save time by using your existing account to sign in to Evening Standard

We'll never share your information or post anything to your account without your permission

Forgot your password ?

Registration

* indicates fields that are mandatory

Email *

Password *

Confirm Password *

First name *

Surname *

Postcode *

Country *

Mobile phone number

Username *

Gender *

Year of birth *

When you sign up...

You will have access to all our online competitions, discounted offers and can post comments on our site.

You will also receive The Weekender newsletter sent every Thursday - it’s full of fantastic offers and ideas for the weekend. You can update your email preferences in your account page when you log in.

Other newsletters and emails

Homes & Property Newsletter - Yes I want to receive the weekly email with all the latest news on property in the capital

Occasionally we would also like to send you relevant emails detailing specific offers either from ourselves or carefully selected partners. If you would prefer not to receive these then please tick the appropriate boxes below. We will never pass on your details.

I do not want to receive additional offers and information from the Evening Standard

I do not want to receive additional offers and information sent by Evening Standard on behalf of carefully selected partners

Terms and Conditions

* I have read, understood and agree to be bound by the terms and conditions of Evening Standard

Registration

Mail Sent for Registration Confirmation.

A confirmation email has been sent. Please activate your account by clicking on the activation link sent in your mail box.

The Medicines and Healthcare products Regulatory Agency (MHRA) ordered Prexige, which has been available in the UK since December 2005, to be withdrawn from the market.

The Agency is now informing healthcare professionals about the suspension of the drug's licence and has advised them not to prescribe it.

A spokesman for the MHRA said the decision had been taken after the Commission on Human Medicines reviewed the latest worldwide data on the safety of Prexige, which is also known as lumiracoxib.

"Importantly, the latest data shows an increase in the number of cases of serious liver reactions that have occurred with the licensed 100mg dose, and in some cases the reactions have been associated with short term use," the spokesman said.

Dr June Raine, Director of Vigilance and Risk Management of Medicines at the MHRA, said: "The MHRA carefully reviewed the latest evidence, and sought independent expert advice from the Commission on Human Medicines.

"In light of the latest data on liver toxicity associated with lumiracoxib, CHM advised that previous measures could not be relied upon to guarantee patient safety.

"Patients taking Prexige should make an appointment to see their doctor at the next convenient opportunity."

Prexige had previously been subjected to prescribing restrictions for patients with current or previous liver problems, and additional requirements for blood tests before and during treatment for other patients.

The drug was used to treat painful symptoms of osteoarthritis of the knee and hip and approximately 8.5 million prescriptions for the treatment have been written worldwide since its launch in July 2005, including to around 5,000 British patients in the past year.